Pharmaceutical - Pharmaceutical, North America, Afinitor


US oncologists' perceptions of Roche's Perjeta very promising


Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

FDA approves pediatric Afinitor from Novartis and Teva's tbo-filgrastim


The US Food and Drug Administration yesterday approved Swiss drug major Novartis' (NOVN: VX) Afinitor…

AfinitorBiotechnologyGenericsNorth AmericaNovartisOncologyPharmaceuticalRegulationSicor Biotechtbo-filgrastimTeva Pharmaceutical Industries

FDA backs Novartis' Afinitor for advanced breast cancer


There was good news for Swiss drug major Novartis (NOVN: VX) on Friday, when the US Food and Drug Administration…

AfinitorNorth AmericaNovartisOncologyPharmaceuticalRegulation

US FDA backs new indications for Votrient and Afinitor


The US Food and Drug Administration last week gave its approval for new indications for currently marketed…

AfinitorGlaxoSmithKlineNorth AmericaNovartisOncologyPharmaceuticalRegulationVotrient

Back to top